Novel, knowledge-based models for the prediction of hydrate and solvate formation are introduced, which require only the molecular formula as input. A dataset of more than 19,000 organic, non-ionic and non-polymeric molecules was extracted from the Cambridge Structural Database. Molecules that formed solvates were compared with those that did not using molecular descriptors and statistical methods, which allowed the identification of chemical properties that contribute to solvate formation. The study was conducted for five types of solvates: ethanol, methanol, dichloromethane, chloroform and water solvates. The identified properties were all related to the size and branching of the molecules and to the hydrogen bonding ability of the molecules. The corresponding molecular descriptors were used to fit logistic regression models to predict the probability of any given molecule to form a solvate. The established models were 2 able to predict the behavior of ~80% of the data correctly using only two descriptors in the predictive model.

Fenofibrate is one of the most commonly prescribed hyperlipidemia agents. Despite its high lipophilicity and ultralow aqueous solubility, most commercially available formulations use micronized crystalline fenofibrate form I, which has a low dissolution rate and poor oral bioavailability. Little is known about the crystallization of other polymorphs from supercooled amorphous fenofibrate. This study reports a new fenofibrate polymorph (form III) obtained via a controlled heterogeneous nucleation method using low quantity (1% w/w) of the generally recognized as safe (GRAS) oral pharmaceutical excipient talc. Form III has a low melting point of 50 °C, and crystallization of form I immediately occurs after the melting of form III. The microscopic, thermal, and spectroscopic characterizations of form III confirmed the distinct molecular packing difference between the new form and other known forms. The discovery of this new form will enrich the understanding of the molecular behavior of fenofibrate and bring useful insights into the role pharmaceutical excipients in selective crystallization of pharmaceutical active ingredients.

Fenofibrate is a dyslipidemia treatment agent. Its crystallisation behaviour is difficult to predict. This study investigated the controllability of its crystallisation by means of regulating the exposed surface and growth temperatures.